BioCatch distribution through Q2 and Alloy
BioCatch
These partnerships turn BioCatch from a tool sold one bank at a time into a fraud layer that can ride inside software already used by hundreds of smaller institutions. Q2 gives BioCatch a distribution path into digital banking apps that regional banks and credit unions already run, while Alloy gives it a way into account opening and identity workflows where fintechs already orchestrate multiple fraud checks. That matters because mid market institutions usually do not buy a standalone behavioral biometrics stack first, they buy it when it shows up pre integrated inside systems they already depend on.
-
Q2 is a channel to banks already operating on a shared digital banking platform. BioCatch joined Q2 Partner Accelerator in February 2024, which means its SDK and risk scoring can be plugged into Q2 powered web and mobile banking flows without each institution building a custom integration from scratch.
-
Alloy is a channel to onboarding and fraud teams. The May 2025 partnership puts BioCatch inside Alloy’s identity and fraud orchestration layer, so a bank or fintech using Alloy for account opening can add BioCatch behavioral signals alongside document checks, device data, and watchlist screening in one decision flow.
-
This channel motion is already showing up in revenue mix. Partner driven ARR exceeded $10 million in Q2 2025 and grew 71% year over year, while BioCatch grew from 152 financial institutions in November 2023 to more than 280 across 25 plus countries by mid 2025, evidence that distribution beyond the largest banks is working.
The next leg is deeper embedding into shared banking infrastructure, not just more direct enterprise sales. If BioCatch becomes a default fraud signal inside platforms like Q2 and Alloy, it can spread through regional banks, credit unions, and fintech programs with lower selling costs, faster deployment, and a much larger base for cross selling scam, mule, and network intelligence products.